skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole

Review

(2199) Views  (854) Full article downloads

Authors: Elizabet V Guimarães, Paula VP Guerra, Francisco J Penna

Published Date October 2010 Volume 2010:6 Pages 531 - 537
DOI: http://dx.doi.org/10.2147/TCRM.S14425

Elizabet V Guimarães, Paula VP Guerra, Francisco J Penna
Department of Pediatrics, Medical School, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Objective: To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on proton pump inhibitors (PPIs), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of PPIs observed in the treatment of GERD in children and adolescents.
Sources: Electronic search of PubMed/Medline and Cochrane Collaboration databases, and of abstracts on DDW, NASPGHAN, and ESPGHAN. We focused on controlled and randomized studies published since 2000 and identified reviews that presented a consensual position, and directives published within the last 10 years.
Main results: PPIs are considered better antisecretory agents than H2-receptor antagonists. Although all PPIs are similar, they are not identical in their pharmacologic properties. For example, the acid-suppressive effect of esomeprazole, the S-isomer of omeprazole, persists for more than 16 hours after administration of the morning dose. Therefore, it can control acidity after night meals better than a single dose of omeprazole. Moreover, the onset of the suppressive effect of esomeprazole is faster. It achieves acid inhibition faster than other PPIs.
Conclusion: Currently, the mainstream treatment for GERD in children is a PPI. Although PPIs are safe drugs, effective in healing erosive esophagitis, and in relieving symptoms, studies with esomeprazole have shown that this drug has as powerful an ability to inhibit acid secretion as omeprazole. It also seems that some pharmacologic properties of esomeprazole are actually better for the treatment of GERD.

Keywords: gastroesophageal reflux, therapy, child, adolescent.






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Bactericidal effects of silver plus titanium dioxide-coated endotracheal tubes on Pseudomonas aeruginosa and Staphylococcus aureus
Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review
Critical appraisal and clinical utility of atosiban in the management of preterm labor
Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
Rare association of prune belly syndrome with pouch colon
Congenital chloride diarrhea: late presentation
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
Intersection of chronic pain treatment and opioid analgesic misuse: causes, treatments, and policy strategies
Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients